GAS5 and neoplasm: This finding was confirmed in NMIBC patients, where decreased GAS5 expression (p = 0.002) in tumours compared to their matched normal counterparts was detected in approximately 69.5% of the enrolled TaT1 patients (Supplementary Fig. 1).